New Zealand health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
Archive — September 2025
Page 5 of 5 of this archive, newest first.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to Japan after 5 consecutive customs detentions
The route did not close because of a rule about peptides.
The lowest effective dose is a real concept with almost no data behind it
What the labels permit, what clinicians do, and the size of the gap between them.
Discontinuation rates, read honestly
The ceiling varies severalfold between people, and nothing measurable at baseline predicts where it sits.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.
What changed at Homopeptide in September, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 29-day notice: how a compounding wind-down works in Argentina
The document is four pages. Three of them are about dates.